Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system: expression, release and interactions with 5-HT1 receptors

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system : expression, release and interactions with 5-HT1 receptors. / Edvinsson, Jacob C. A.; Maddahi, Aida; Christiansen, Isabella M.; Reducha, Philip V.; Warfvinge, Karin; Sheykhzade, Majid; Edvinsson, Lars; Haanes, Kristian A.

In: The Journal of Headache and Pain, Vol. 23, 26, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Edvinsson, JCA, Maddahi, A, Christiansen, IM, Reducha, PV, Warfvinge, K, Sheykhzade, M, Edvinsson, L & Haanes, KA 2022, 'Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system: expression, release and interactions with 5-HT1 receptors', The Journal of Headache and Pain, vol. 23, 26. https://doi.org/10.1186/s10194-022-01394-z

APA

Edvinsson, J. C. A., Maddahi, A., Christiansen, I. M., Reducha, P. V., Warfvinge, K., Sheykhzade, M., Edvinsson, L., & Haanes, K. A. (2022). Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system: expression, release and interactions with 5-HT1 receptors. The Journal of Headache and Pain, 23, [26]. https://doi.org/10.1186/s10194-022-01394-z

Vancouver

Edvinsson JCA, Maddahi A, Christiansen IM, Reducha PV, Warfvinge K, Sheykhzade M et al. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system: expression, release and interactions with 5-HT1 receptors. The Journal of Headache and Pain. 2022;23. 26. https://doi.org/10.1186/s10194-022-01394-z

Author

Edvinsson, Jacob C. A. ; Maddahi, Aida ; Christiansen, Isabella M. ; Reducha, Philip V. ; Warfvinge, Karin ; Sheykhzade, Majid ; Edvinsson, Lars ; Haanes, Kristian A. / Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system : expression, release and interactions with 5-HT1 receptors. In: The Journal of Headache and Pain. 2022 ; Vol. 23.

Bibtex

@article{64e04c0d89494e439266d41e692094c7,
title = "Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system: expression, release and interactions with 5-HT1 receptors",
abstract = "BACKGROUND: 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migraine attacks and inhibit the in vivo release of calcitonin gene-related peptide (CGRP) in human and animal models. The study aimed to examine the localization, genetic expression and functional aspects of 5- HT 1B/1D/1F receptors in the trigeminal system in order to further understand the molecular sites of action of triptans (5-HT 1B/1D) and ditans (5-HT 1F). METHODS: Utilizing immunohistochemistry, the localization of 5-HT and of 5-HT 1B/1D/1F receptors was examined in rat trigeminal ganglion (TG) and combined with quantitative polymerase chain reaction to quantify the level of expression for 5-HT 1B/1D/1F receptors in the TG. The functional role of these receptors was examined ex vivo with a capsaicin/potassium induced 5-HT and CGRP release. RESULTS: 5-HT immunoreactivity (ir) was observed in a minority of CGRP negative C-fibres, most neuron somas and faintly in A-fibres and Schwann cell neurolemma. 5-HT 1B/1D receptors were expressed in the TG, while the 5-HT 1F receptor displayed a weak ir. The 5-HT 1D receptor co-localized with receptor activity-modifying protein 1 (RAMP1) in Aδ-fibres in the TG, while 5-HT 1B-ir was weakly expressed and 5-HT 1F-ir was not detected in these fibres. None of the 5-HT 1 receptors co-localized with CGRP-ir in C-fibres. 5-HT 1D receptor mRNA was the most prominently expressed, followed by the 5-HT 1B receptor and lastly the 5-HT 1F receptor. The 5-HT 1B and 5-HT 1D receptor antagonist, GR127935, could reverse the inhibitory effect of Lasmiditan (a selective 5-HT 1F receptor agonist) on CGRP release in the soma-rich TG but not in soma-poor TG or dura mater. 5-HT release in the soma-rich TG, and 5-HT content in the baseline samples, negatively correlated with CGRP levels, showing for the first time a physiological role for 5-HT induced inhibition. CONCLUSION: This study reveals the presence of a subgroup of C-fibres that store 5-HT. The data shows high expression of 5-HT 1B/1D receptors and suggests that the 5-HT 1F receptor is a relatively unlikely target in the rat TG. Furthermore, Lasmiditan works as a partial agonist on 5-HT 1B/1D receptors in clinically relevant dose regiments. ",
author = "Edvinsson, {Jacob C. A.} and Aida Maddahi and Christiansen, {Isabella M.} and Reducha, {Philip V.} and Karin Warfvinge and Majid Sheykhzade and Lars Edvinsson and Haanes, {Kristian A.}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
doi = "10.1186/s10194-022-01394-z",
language = "English",
volume = "23",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system

T2 - expression, release and interactions with 5-HT1 receptors

AU - Edvinsson, Jacob C. A.

AU - Maddahi, Aida

AU - Christiansen, Isabella M.

AU - Reducha, Philip V.

AU - Warfvinge, Karin

AU - Sheykhzade, Majid

AU - Edvinsson, Lars

AU - Haanes, Kristian A.

N1 - © 2022. The Author(s).

PY - 2022

Y1 - 2022

N2 - BACKGROUND: 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migraine attacks and inhibit the in vivo release of calcitonin gene-related peptide (CGRP) in human and animal models. The study aimed to examine the localization, genetic expression and functional aspects of 5- HT 1B/1D/1F receptors in the trigeminal system in order to further understand the molecular sites of action of triptans (5-HT 1B/1D) and ditans (5-HT 1F). METHODS: Utilizing immunohistochemistry, the localization of 5-HT and of 5-HT 1B/1D/1F receptors was examined in rat trigeminal ganglion (TG) and combined with quantitative polymerase chain reaction to quantify the level of expression for 5-HT 1B/1D/1F receptors in the TG. The functional role of these receptors was examined ex vivo with a capsaicin/potassium induced 5-HT and CGRP release. RESULTS: 5-HT immunoreactivity (ir) was observed in a minority of CGRP negative C-fibres, most neuron somas and faintly in A-fibres and Schwann cell neurolemma. 5-HT 1B/1D receptors were expressed in the TG, while the 5-HT 1F receptor displayed a weak ir. The 5-HT 1D receptor co-localized with receptor activity-modifying protein 1 (RAMP1) in Aδ-fibres in the TG, while 5-HT 1B-ir was weakly expressed and 5-HT 1F-ir was not detected in these fibres. None of the 5-HT 1 receptors co-localized with CGRP-ir in C-fibres. 5-HT 1D receptor mRNA was the most prominently expressed, followed by the 5-HT 1B receptor and lastly the 5-HT 1F receptor. The 5-HT 1B and 5-HT 1D receptor antagonist, GR127935, could reverse the inhibitory effect of Lasmiditan (a selective 5-HT 1F receptor agonist) on CGRP release in the soma-rich TG but not in soma-poor TG or dura mater. 5-HT release in the soma-rich TG, and 5-HT content in the baseline samples, negatively correlated with CGRP levels, showing for the first time a physiological role for 5-HT induced inhibition. CONCLUSION: This study reveals the presence of a subgroup of C-fibres that store 5-HT. The data shows high expression of 5-HT 1B/1D receptors and suggests that the 5-HT 1F receptor is a relatively unlikely target in the rat TG. Furthermore, Lasmiditan works as a partial agonist on 5-HT 1B/1D receptors in clinically relevant dose regiments.

AB - BACKGROUND: 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migraine attacks and inhibit the in vivo release of calcitonin gene-related peptide (CGRP) in human and animal models. The study aimed to examine the localization, genetic expression and functional aspects of 5- HT 1B/1D/1F receptors in the trigeminal system in order to further understand the molecular sites of action of triptans (5-HT 1B/1D) and ditans (5-HT 1F). METHODS: Utilizing immunohistochemistry, the localization of 5-HT and of 5-HT 1B/1D/1F receptors was examined in rat trigeminal ganglion (TG) and combined with quantitative polymerase chain reaction to quantify the level of expression for 5-HT 1B/1D/1F receptors in the TG. The functional role of these receptors was examined ex vivo with a capsaicin/potassium induced 5-HT and CGRP release. RESULTS: 5-HT immunoreactivity (ir) was observed in a minority of CGRP negative C-fibres, most neuron somas and faintly in A-fibres and Schwann cell neurolemma. 5-HT 1B/1D receptors were expressed in the TG, while the 5-HT 1F receptor displayed a weak ir. The 5-HT 1D receptor co-localized with receptor activity-modifying protein 1 (RAMP1) in Aδ-fibres in the TG, while 5-HT 1B-ir was weakly expressed and 5-HT 1F-ir was not detected in these fibres. None of the 5-HT 1 receptors co-localized with CGRP-ir in C-fibres. 5-HT 1D receptor mRNA was the most prominently expressed, followed by the 5-HT 1B receptor and lastly the 5-HT 1F receptor. The 5-HT 1B and 5-HT 1D receptor antagonist, GR127935, could reverse the inhibitory effect of Lasmiditan (a selective 5-HT 1F receptor agonist) on CGRP release in the soma-rich TG but not in soma-poor TG or dura mater. 5-HT release in the soma-rich TG, and 5-HT content in the baseline samples, negatively correlated with CGRP levels, showing for the first time a physiological role for 5-HT induced inhibition. CONCLUSION: This study reveals the presence of a subgroup of C-fibres that store 5-HT. The data shows high expression of 5-HT 1B/1D receptors and suggests that the 5-HT 1F receptor is a relatively unlikely target in the rat TG. Furthermore, Lasmiditan works as a partial agonist on 5-HT 1B/1D receptors in clinically relevant dose regiments.

U2 - 10.1186/s10194-022-01394-z

DO - 10.1186/s10194-022-01394-z

M3 - Journal article

C2 - 35177004

VL - 23

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

M1 - 26

ER -

ID: 297058687